vs

Side-by-side financial comparison of CENTERSPACE (CSR) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $66.6M, roughly 1.1× CENTERSPACE). CENTERSPACE runs the higher net margin — -27.7% vs -49.0%, a 21.4% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 0.3%). CENTERSPACE produced more free cash flow last quarter ($64.3M vs $-84.7M).

Centerspace is a real estate investment company specializing in the ownership, operation, and development of high-quality multifamily residential properties. Its core operating markets cover the U.S. Midwest and Mountain West regions, serving diverse renter segments with both affordable and premium housing options, while focusing on tenant experience and long-term asset value growth.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

CSR vs VRDN — Head-to-Head

Bigger by revenue
VRDN
VRDN
1.1× larger
VRDN
$70.6M
$66.6M
CSR
Growing faster (revenue YoY)
VRDN
VRDN
+81957.8% gap
VRDN
81958.1%
0.3%
CSR
Higher net margin
CSR
CSR
21.4% more per $
CSR
-27.7%
-49.0%
VRDN
More free cash flow
CSR
CSR
$149.0M more FCF
CSR
$64.3M
$-84.7M
VRDN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CSR
CSR
VRDN
VRDN
Revenue
$66.6M
$70.6M
Net Profit
$-18.4M
$-34.6M
Gross Margin
96.5%
Operating Margin
-15.9%
-56.7%
Net Margin
-27.7%
-49.0%
Revenue YoY
0.3%
81958.1%
Net Profit YoY
-262.9%
54.9%
EPS (diluted)
$-1.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CSR
CSR
VRDN
VRDN
Q4 25
$66.6M
Q3 25
$71.4M
$70.6M
Q2 25
$68.5M
Q1 25
$67.1M
Q4 24
$66.4M
Q3 24
$65.0M
Q2 24
$65.0M
Q1 24
$64.5M
Net Profit
CSR
CSR
VRDN
VRDN
Q4 25
$-18.4M
Q3 25
$53.8M
$-34.6M
Q2 25
$-14.5M
Q1 25
$-3.7M
Q4 24
$-5.1M
Q3 24
$-1.0M
Q2 24
$-1.3M
Q1 24
$-3.9M
Gross Margin
CSR
CSR
VRDN
VRDN
Q4 25
96.5%
Q3 25
96.5%
Q2 25
96.5%
Q1 25
96.4%
Q4 24
96.5%
Q3 24
96.6%
Q2 24
96.6%
Q1 24
96.4%
Operating Margin
CSR
CSR
VRDN
VRDN
Q4 25
-15.9%
Q3 25
-56.7%
Q2 25
-9.9%
Q1 25
7.1%
Q4 24
4.3%
Q3 24
9.8%
Q2 24
11.1%
Q1 24
6.3%
Net Margin
CSR
CSR
VRDN
VRDN
Q4 25
-27.7%
Q3 25
75.3%
-49.0%
Q2 25
-21.2%
Q1 25
-5.6%
Q4 24
-7.6%
Q3 24
-1.6%
Q2 24
-2.0%
Q1 24
-6.1%
EPS (diluted)
CSR
CSR
VRDN
VRDN
Q4 25
$-1.08
Q3 25
$3.19
Q2 25
$-0.87
Q1 25
$-0.22
Q4 24
$-0.31
Q3 24
$-0.40
Q2 24
$-0.19
Q1 24
$-0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CSR
CSR
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$12.8M
$490.9M
Total DebtLower is stronger
$1.0B
Stockholders' EquityBook value
$719.2M
$503.0M
Total Assets
$1.9B
$577.1M
Debt / EquityLower = less leverage
1.42×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CSR
CSR
VRDN
VRDN
Q4 25
$12.8M
Q3 25
$12.9M
$490.9M
Q2 25
$12.4M
Q1 25
$11.9M
Q4 24
$12.0M
Q3 24
$14.5M
Q2 24
$14.3M
Q1 24
$12.7M
Total Debt
CSR
CSR
VRDN
VRDN
Q4 25
$1.0B
Q3 25
$1.1B
Q2 25
$1.1B
Q1 25
$955.5M
Q4 24
$955.4M
Q3 24
$921.3M
Q2 24
$931.7M
Q1 24
$929.1M
Stockholders' Equity
CSR
CSR
VRDN
VRDN
Q4 25
$719.2M
Q3 25
$748.6M
$503.0M
Q2 25
$710.1M
Q1 25
$636.8M
Q4 24
$752.0M
Q3 24
$672.5M
Q2 24
$680.7M
Q1 24
$688.1M
Total Assets
CSR
CSR
VRDN
VRDN
Q4 25
$1.9B
Q3 25
$2.1B
$577.1M
Q2 25
$2.0B
Q1 25
$1.9B
Q4 24
$1.9B
Q3 24
$1.9B
Q2 24
$1.9B
Q1 24
$1.9B
Debt / Equity
CSR
CSR
VRDN
VRDN
Q4 25
1.42×
Q3 25
1.53×
Q2 25
1.57×
Q1 25
1.50×
Q4 24
1.27×
Q3 24
1.37×
Q2 24
1.37×
Q1 24
1.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CSR
CSR
VRDN
VRDN
Operating Cash FlowLast quarter
$98.5M
$-84.6M
Free Cash FlowOCF − Capex
$64.3M
$-84.7M
FCF MarginFCF / Revenue
96.5%
-120.1%
Capex IntensityCapex / Revenue
51.3%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$125.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CSR
CSR
VRDN
VRDN
Q4 25
$98.5M
Q3 25
$35.1M
$-84.6M
Q2 25
$25.3M
Q1 25
$25.4M
Q4 24
$98.2M
Q3 24
$32.3M
Q2 24
$22.9M
Q1 24
$24.4M
Free Cash Flow
CSR
CSR
VRDN
VRDN
Q4 25
$64.3M
Q3 25
$25.7M
$-84.7M
Q2 25
$15.5M
Q1 25
$20.4M
Q4 24
$41.6M
Q3 24
$20.5M
Q2 24
$9.1M
Q1 24
$2.6M
FCF Margin
CSR
CSR
VRDN
VRDN
Q4 25
96.5%
Q3 25
36.0%
-120.1%
Q2 25
22.7%
Q1 25
30.4%
Q4 24
62.6%
Q3 24
31.5%
Q2 24
14.0%
Q1 24
4.0%
Capex Intensity
CSR
CSR
VRDN
VRDN
Q4 25
51.3%
Q3 25
13.1%
0.2%
Q2 25
14.2%
Q1 25
7.5%
Q4 24
85.3%
Q3 24
18.2%
Q2 24
21.2%
Q1 24
33.8%
Cash Conversion
CSR
CSR
VRDN
VRDN
Q4 25
Q3 25
0.65×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CSR
CSR

Multi Family Residential$57.3M86%
Other$8.1M12%
Other Property Revenue$1.2M2%

VRDN
VRDN

Segment breakdown not available.

Related Comparisons